CHRS - Coherus BioSciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
18.52
-0.34 (-1.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close18.86
Open18.90
Bid0.00 x 800
Ask0.00 x 2200
Day's Range18.44 - 19.27
52 Week Range8.32 - 23.43
Volume482,595
Avg. Volume1,064,274
Market Cap1.285B
Beta (3Y Monthly)2.24
PE Ratio (TTM)N/A
EPS (TTM)-2.75
Earnings DateAug 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.00
Trade prices are not sourced from all markets
  • Top Ranked Momentum Stocks to Buy for July 12th
    Zacks5 days ago

    Top Ranked Momentum Stocks to Buy for July 12th

    Top Ranked Momentum Stocks to Buy for July 12th

  • Motley Fool9 days ago

    Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today

    Bad news on multiple fronts hit stocks.

  • Here's Why Coherus BioSciences Is Falling Today
    Motley Fool9 days ago

    Here's Why Coherus BioSciences Is Falling Today

    The business reported an upbeat update, but something got lost in translation on Wall Street.

  • Are Investors Undervaluing Coherus BioSciences, Inc. (NASDAQ:CHRS) By 20%?
    Simply Wall St.9 days ago

    Are Investors Undervaluing Coherus BioSciences, Inc. (NASDAQ:CHRS) By 20%?

    Today we will run through one way of estimating the intrinsic value of Coherus BioSciences, Inc. (NASDAQ:CHRS) by...

  • GlobeNewswire9 days ago

    Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA® Net Sales of $79 Million to $84 Million

    Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ expectations regarding the continued adoption of UDENYCA® in the U.S., estimation of channel mix, returns, chargebacks and rebates, each of which impact net sales computation. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made.

  • GlobeNewswire9 days ago

    Coherus BioSciences to Report Second Quarter Financial Results on August 1st

    REDWOOD CITY, Calif., July 08, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its second quarter 2019 financial results will.

  • GlobeNewswire16 days ago

    Coherus BioSciences Production Exceeds Four-Hundred Thousand UDENYCA® (pegfilgrastim-cbqv) Pre-Filled Syringes

    Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA® pre-filled syringes to date. The cumulative production of 400,000 UDENYCA® pre-filled syringes is a significant milestone, as it represents approximately one-third of the annual utilization of pegfilgrastim in the United States. “Coherus provides unencumbered choice of pegfilgrastim product to patients and providers in the United States," said Denny Lanfear, President and CEO of Coherus.

  • Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why
    Zacks20 days ago

    Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why

    Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire26 days ago

    Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., June 21, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective June 20, 2019, the compensation committee of the company’s board.

  • Hedge Funds Have Never Been This Bullish On Coherus Biosciences Inc (CHRS)
    Insider Monkeylast month

    Hedge Funds Have Never Been This Bullish On Coherus Biosciences Inc (CHRS)

    Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]

  • Markitlast month

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    Coherus BioSciences Inc NASDAQ NMS:CHRSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for CHRS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 22. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding CHRS is favorable, with net inflows of $2.33 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Amgen (AMGN) Offers to Acquire Drug Discovery Platform
    Zacks2 months ago

    Amgen (AMGN) Offers to Acquire Drug Discovery Platform

    Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.

  • Did Coherus BioSciences's (NASDAQ:CHRS) Share Price Deserve to Gain 29%?
    Simply Wall St.2 months ago

    Did Coherus BioSciences's (NASDAQ:CHRS) Share Price Deserve to Gain 29%?

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...

  • GlobeNewswire2 months ago

    Coherus BioSciences Management to Present at Jefferies 2019 Global Healthcare Conference

    REDWOOD CITY, Calif., May 22, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the Jefferies 2019 Global Healthcare.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CHRS earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Coherus BioSciences Inc Earnings Call

  • Barrons.com2 months ago

    2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan

    Health-care stocks and drugmakers have suffered from pre-election worries, but JPMorgan says there are still some worth buying.

  • Coherus BioSciences, Inc. (CHRS) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Coherus BioSciences, Inc. (CHRS) Q1 2019 Earnings Call Transcript

    CHRS earnings call for the period ending March 31, 2019.

  • Coherus BioSciences (CHRS) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Coherus BioSciences (CHRS) Reports Q1 Loss, Tops Revenue Estimates

    Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 36.96% and 0.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Coherus BioSciences: 1Q Earnings Snapshot

    The Redwood City, California-based company said it had a loss of 29 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Coherus BioSciences Reports Corporate Highlights and First Quarter 2019 Financial Results

    REDWOOD CITY, Calif., May 09, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today reviewed corporate highlights and reported financial results.

  • Did Hedge Funds Drop The Ball On Coherus Biosciences Inc (CHRS) ?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On Coherus Biosciences Inc (CHRS) ?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • GlobeNewswire2 months ago

    Coherus BioSciences and Amgen Settle Trade Secrets Action

    Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Amgen and Coherus have settled the trade secret action brought by Amgen against Coherus that was pending in the Superior Court of California County of Ventura. The details of the settlement are confidential but Coherus will continue to market UDENYCA® and will pay a mid-single digit royalty to Amgen for five years. As announced, Coherus will host a conference call on Thursday, May 9, 2019 starting at 4:30 p.m. ET to provide first quarter 2019 financial results and provide a general business update.